Frazier Life Sciences Management L.P. boosted its stake in shares of Allogene Therapeutics, Inc. (NASDAQ: ALLO) by 491.2% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 22,446,668 shares of the company's stock after acquiring an additional 18,650,000 shares during the quarter.

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that Geoffrey Parker, Executive Vice President and Chief Financial Officer, will retire effective November 6, 2026.

Deutsche Bank AG bought a new stake in Allogene Therapeutics, Inc. (NASDAQ: ALLO) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 281,949 shares of the company's stock, valued at approximately $586,000. Deutsche Bank AG owned about 0.08% of Allogene

Connor Clark and Lunn Investment Management Ltd. purchased a new position in shares of Allogene Therapeutics, Inc. (NASDAQ: ALLO) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 322,827 shares of the company's stock, valued at approximately $671,000. Connor Clark

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will participate in the following upcoming investor conference in September.